%0 Journal Article
%@ 1438-8871
%I JMIR Publications
%V 26
%N 
%P e51239
%T Information and Communications Technology–Based Monitoring Service for Tailored Chronic Disease Management in Primary Care: Cost-Effectiveness Analysis Based on ICT-CM Trial Results
%A Oh,Sung-Hee
%A Kang,Jae-Heon
%A Kwon,Jin-Won
%+ Brain Korea 21 Four Community-Based Intelligent Novel Drug Discovery Education Unit, College of Pharmacy and Research Institute of Pharmaceutical Sciences, Kyungpook National University, 80, Daehak-ro, Buk-gu, Daegu, 41566, Republic of Korea, 82 53 950 8580, jwkwon@knu.ac.kr
%K mHealth
%K mobile health
%K smartphone application
%K cost-effectiveness analysis
%K hypertension
%K diabetes mellitus
%K primary care
%K artificial intelligence
%K applications digital health
%K mobile phone
%D 2024
%7 11.10.2024
%9 Original Paper
%J J Med Internet Res
%G English
%X Background: Information and communications technology–based tailored management (TM) intervention is a novel automatic system in which a smartphone app for the management of patients with hypertension and diabetes, the provider web, and Bluetooth devices are linked. However, little evidence exists regarding the cost-effectiveness of the interventions using mobile apps. Objective: This study aimed to assess the cost-effectiveness of TM intervention for adult patients with hypertension or diabetes in primary care compared with usual care (UC). Methods: Cost-effectiveness analysis using a Markov model was conducted from the Korean health care system perspective. Based on 6-month outcome data from an information and communications technology–based tailored chronic disease management (ICT-CM) trial, effectiveness over a lifetime beyond the trial periods was extrapolated using a cardiovascular disease risk prediction model. Costs were estimated using ICT-CM trial data and national health insurance claims data. Health utility weights were obtained from the Korea National Health and Nutrition Examination Survey. Results: In the base-case analysis, compared with UC, TM was more costly (US $23,157 for TM vs US $22,391 for UC) and more effective (12.006 quality-adjusted life-years [QALYs] for TM vs 11.868 QALYs for UC). The incremental cost-effectiveness ratio was US $5556 per QALY gained. Probabilistic sensitivity analysis showed that the probability of TM being cost-effective compared with UC was approximately 97% at an incremental cost-effectiveness ratio threshold of US $26,515 (KRW 35 million) per QALY gained. Conclusions: Compared with UC, TM intervention is a cost-effective option for patients with hypertension or diabetes in primary care settings. The study results can assist policy makers in making evidence-based decisions when implementing accessible chronic disease management services. 
%R 10.2196/51239
%U https://www.jmir.org/2024/1/e51239
%U https://doi.org/10.2196/51239